期刊文献+

结直肠癌肝转移肝切除术前门静脉栓塞临床疗效的Meta分析 被引量:11

Clinical effectiveness of preoperative portal vein embolization in the treatment of colorectal cancer liver metastases: a meta-analysis
原文传递
导出
摘要 目的 探讨在结直肠癌肝转移(CRLM)治疗中肝切除术前门静脉栓塞(PVE)的临床疗效.方法 通过检索PubMed、EMBASE、CBM等据库,收集公开发表的有关比较肝切除术前PVE与无需PVE直接手术临床疗效的对照研究,对两组的术后并发症发生率、肝衰竭发生率、死亡率及5年生存率进行Meta分析.结果 共纳入文献8篇,676例患者,其中术前PVE组253例,直接手术组423例,分析显示术前PVE组术后并发症发生率高于直接手术组[比值比(OR)=1.91,95%可信区间(CI):1.02 ~2.15,P<0.05],术前PVE组与直接手术组术后肝衰竭发生率(OR=0.66,95% CI:0.34~1.30)、死亡率(OR=1.14,95% CI:0.43 ~3.01)、5年生存率[风险比(HR)=1.00,95% CI:0.73 ~ 1.36]的差异均无统计学意义(P>0.05).结论 肝切除术前PVE可使预计术后残存肝脏容积不够、手术风险大而被视为不可切除的肝转移患者获得相对安全的手术切除机会,其远期预后与无需PVE的初诊可切除患者相当. Objective To investigate the clinical effectiveness of preoperative portal vein embolization (PVE) in the treatment of colorectal cancer liver metastases (CRLM).Methods All eligible case-control studies comparing the clinical effectiveness of preoperative PVE or without PVE before hepatectomy were searched out from PubMed,EMBASE and CBM database.Data on the rate of postoperative complications,liver failure and mortality and the 5-year overall survival rate were meta-analyzed.Results A total of 8 studies comprising 676 patients were included,including 253 patients in the PVE group and 423 patients in the no PVE group.The rate of postoperative complications was higher in the PVE group than in the no PVE group,and there were no significant differences in the rate of postoperative liver failure and mortality and the 5-year overall survival rate between the two groups.Conclusion Patients with unresectable liver metastases because of insufficient future liver remnant and high risk of surgery could get a chance of relative safe resection,and the long-term results were comparable to the patients with initially resectable liver metastases which didn' t need PVE.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2015年第6期1418-1420,共3页 Chinese Journal of Experimental Surgery
基金 国家自然科学基金资助项目(81072152) 湖北省自然科学基金资助项目(2009CD201) 湖北省卫生厅科研资助项目(2013.JX6B20)
关键词 结直肠癌肝转移 门静脉栓塞术 残存肝脏容积 肝切除术 预后 Colorectal liver metastases Portal vein embolization Future liver remnant Hepatectomy Prognosis
  • 相关文献

参考文献16

  • 1吴晓凤,樊嘉,林芷英,纪元.选择性门静脉栓塞的实验研究[J].中华实验外科杂志,2000,17(3):270-270. 被引量:5
  • 2Elias D, Ouellet JF, De Baere T, et al. Preoperative selective portal vein embolization before hepatectomy for liver metastases: long-term results and impact on survival [ J ]. Surgery,2002,131 ( 3 ) : 294 -299.
  • 3Azoulay D, Castaing D, Small A, et al. Resection of nonresectable liv- er metastases from colorectal cancer after percutaneous portal vein em- bolization [ J ]. Ann Surg,2000,231 (4) :480-486.
  • 4Ardito F, Vellone M, Barbaro B, et al. Right and extended-right hep- atectomies for unilobar colorectal metastases : impact of portal vein em- bolization on long-term outcome and liver recurrence [ J ]. Surgery, 2013,153 (6):801-810.
  • 5Lindner P, Cahlin C, Friman S, et al. Extended fight-sided liver re- section for colorectal liver metastases-impact of percutaneous portal venous embolisation [ J ]. Eur J Surg Oncol, 2006,32 ( 3 ) : 292 -296.
  • 6Pameeha V, Glantzounis G, Davies N, et al. Long-term survival and disease recurrence following portal vein embolisation prior to major hepatectomy for colorectal metastases[ J]. Ann Surg Oncol,2009. , 16 (5) : 1202-1207.
  • 7Shindoh J, Tzeng CW, Aloia TA, et al. Portal vein embolization im- proves rate of resection of extensive colorectal liver metastases without worsening survival[ J]. Br J Surg,2013,100( 13 ) : 1777-1783.
  • 8Speh L,Norman P, Tirnqvist L, et al. Combined portal vein emboli- zation and preoperative chemotherapy prior to liver resection for color- ectal cancer metastases [ J]. Scand J Gastrocnterol,2012,47 ( 8-9 ) : 975-983.
  • 9Yamashita S, Hasegawa K, Takahashi M, et al. One-stage hepatectomy following portal vein embolization for colorectal liver metastasis [ J ]. World J Surg,2013,37 ( 3 ) :622-628.
  • 10Zboril P, Yyslouzil K, Klementa I, et al. The significance of portal vein embolization in the treatment of colorectal liver metastases [ J ]. Neoplasma ,2012,59 (2) : 175-182.

二级参考文献30

  • 1刘海,郑维,李远明,杨文龙.大肠癌患者外周血调节性T细胞的检测及临床意义[J].中华实验外科杂志,2007,24(5):626-627. 被引量:11
  • 2万德森.结直肠癌肝转移治疗的进展[J].癌症,1997,16(1):1-4. 被引量:23
  • 3马向涛,余力伟,付静.趋化因子受体CCR6/CCL20在结直肠癌肝转移中的作用[J].中华实验外科杂志,2007,24(8):910-912. 被引量:8
  • 4Doherty DG,O' Farrelly C.Innate and adaptive Iymphoid cells in the human liver.Immunol Rev,2000,174:5-20.
  • 5Bouche O,Beretta GD,Alfonso PG,et al.The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.Cancer Treat Rev,2010,36:s1-10.
  • 6Zhang L,Conejo-Garcia JR,Katsaros D,et al.Intratumoral T cells,recurrence,and survival in epithelial ovarian cancer.N Engl J Med,2003,348:203-213.
  • 7Peng Y,Laouar Y,Li MO,et al.TGF-beta regulates in vivo expansion of Foxp3-expressing CD4 + CD25 + regulatory T cells responsible for protection against diabetes.Proc Natl Acad Sci USA,2004,101:4572-4.577.
  • 8Matzaraki V,Alexandraki KI,Venetsanou K,et al.Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis.Clinical Biochemistry,2007,40:336-342.
  • 9Hattori E,Okumoto K,Adachi T,et al.Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma.Hepatology Research,2003,27:308-313.
  • 10Olson TS,Ley K.Chemokines and chemokine receptors in leukocyte trafficking.Am J Physiol Regul Integr Comp Physiol,2002,283:7-28.

共引文献12

同被引文献92

  • 1Fabrizio Panaro,Fabio Giannone,Benjamin Riviere,Olivia Sgarbura,Caterina Cusumano,Emmanuel Deshayes,Francis Navarro,Boris Guiu,Francois Quenet.Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center[J].Hepatobiliary Surgery and Nutrition,2019,8(4):329-337. 被引量:16
  • 2Lochan R,White SA,Manas DM,et al.Liver resection for colorectal liver met.astasis[J].Surg Oncol,2007,16(1):33-45.
  • 3Adam R,Hoti E,Folprecht G,et al.Accomplishments in 2008 in the management of curable metastatic colorectal cancer[J].Gas- trointest Canrer Res,2009,3(suppl 2):15-22.
  • 4Adams RB,Aloia TA,Loyer E,et al.Selection for hepatic resec- tion of colorectal liver metastases:expert consensus statement [J].HPB(Oxford),2013,15(2):91-103.
  • 5Power DG,Kemeny NE.Chemotherapy for the conversion of un- Tesectable colorectal cancer liver metastases to resection [J],Crit Rev Oncol Hematol,2011,79(3):251-264.
  • 6Adam R,Pascal G,Castaing D,et al.Tumor progression while on chemotherapy:a contraindication to liver resection for multiple colorectal metastases?[J].Ann Surg,2004,240(6):1052-1061.
  • 7Ellis LM,Curley SA,Grothey A.Surgical resection after down- sizing of colorectal liver metastasis in the era of bevacizumab [J].J Clin Oncol,2005,23(22):4853-4855.
  • 8Toumigand C,Cervantes A,Figer A,et al.0PTIM0X1:a ran- domized study of F0LF0X4 or F0LF0X7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer a GERCOR StudytJ].J Clin Oncol,2006,24(3):394-400.
  • 9Masi G,Cupini S,Marcucci L,et al.Treatment with 5-fluoroura- cil/folinic acid,oxaliplatin,and irinotecan enables surgical re- section of metastases in patients with initially unresectahle meta- static colorectal cancer[J].Ann Surg Oncol,2006,13(1):58-65.
  • 10Van Cutsem E,Kohne CH,Ldng I,et al.Cetuximab plus irinote- can,fluorouracil,and leucovorin as first-line treatment for meta- static colorectal cancer:updated analysis of overall survival ac- cording to tumor KRAS and BRAF mutation status [J].J Clin Oncol,2011,29(15):2011-2019.

引证文献11

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部